Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2012

01.12.2012 | original report

Results of children with renal tumors treated in the Austrian–Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria

verfasst von: Claudia Zimmermann, Ulrike Pötschger, Gabriele Amann, Ernst Horcher, Karin Dieckmann, Karoly Lakatos, Christian Urban, Herwig Lackner, Michael Höllwarth, Bernhard Meister, Roman Crazzolara, Georg Ebetsberger, Franz Martin Fink, Neil Jones, Agnes Gamper, Reinhard Moser, Reinhold Kerbl, Barbara Jauk, Walter Pobegen, Martin Henkel, Bernd Ausserer, Waltraud Friesenbichler, Judith Böhm, Norbert Graf, Wolfgang Holter, Helmut Gadner, Andreas Zoubek, Leo Kager, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The overall outcome for children with nephroblastomas is excellent when treated according to protocols that include surgery, chemotherapy, and, in selected cases, radiotherapy. This study was conducted to provide population-based data on Austrian children who had been treated in neoadjuvant nephroblastoma trials between October 1988 and July 2001. One hundred and forty-eight children with newly diagnosed untreated renal tumors were registered in the Austrian–Hungarian Wilms Tumor Study (AHWTS) 1989 (N = 63) and the SIOP 93-01/GPOH Study (N = 85). After a median follow-up of 11.8 years from diagnosis, 130 patients have been reported to be alive; 18 patients have died. Three patients had carcinoma and three had nephroblastomatosis; the 5-year event-free survival (EFS) and overall survival (OS) rates for the remaining 142 patients were 83 ± 3 % and 91 ± 2 %, respectively (SIOP 93-01/GPOH trial, 5-year EFS 85 ± 4 %, OS 95 ± 2 %; AHWTS 1989 trial, 5-year EFS 79 ± 5 %, OS 86 ± 5 %). Outcome was better for low-risk pathology (N = 14; 5-year EFS 92 ± 8 %, OS 100 %) than for intermediate-risk (N = 106; 5-year EFS 89 ± 3 %, OS 94 ± 2 %) and high-risk pathology (N = 22; 5-year EFS 50 ± 11 %, OS 68 ± 10 %; P < 0.001). The stage of the disease was correlated with outcome; stages I–III (N = 102; 5-year EFS 90 ± 3 %, OS 95 ± 2 %), stage IV (N = 25; 5-year EFS 56 ± 10 %, OS 76 ± 9 %), and stage V (N = 15; 5-year EFS 80 ± 10 %, OS 87 ± 9 %; P = 0.008). On the basis of the expected incidence for renal tumors in childhood, these data provide evidence that almost all children with these diseases in Austria had been recruited in the respective treatment trials (mean: 12 patients/year); and the outcomes are comparable to international results.
Literatur
2.
Zurück zum Zitat Gooskens SL, Furtwängler R, Vujanic GM, et al. Clear cell sarcoma of the kidney: a review. Eur J Cancer. 2012;48(14):2219–26.PubMedCrossRef Gooskens SL, Furtwängler R, Vujanic GM, et al. Clear cell sarcoma of the kidney: a review. Eur J Cancer. 2012;48(14):2219–26.PubMedCrossRef
3.
Zurück zum Zitat Van Den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, et al. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. Pediatr Blood Cancer. 2011;56(5):733–7.PubMedCrossRef Van Den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, et al. Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. Pediatr Blood Cancer. 2011;56(5):733–7.PubMedCrossRef
4.
Zurück zum Zitat Luithle T, Szavay P, Furtwängler R, et al. Treatment of cystic nephroma and cystic partially differentiated nephroblastoma—a report from the SIOP/GPOH study group. J Urol. 2007;177(1):294–6.PubMedCrossRef Luithle T, Szavay P, Furtwängler R, et al. Treatment of cystic nephroma and cystic partially differentiated nephroblastoma—a report from the SIOP/GPOH study group. J Urol. 2007;177(1):294–6.PubMedCrossRef
6.
Zurück zum Zitat Geller E, Kochan PS. Renal neoplasms of childhood. Radiol Clin North Am. 2011;49(4):689–709.PubMedCrossRef Geller E, Kochan PS. Renal neoplasms of childhood. Radiol Clin North Am. 2011;49(4):689–709.PubMedCrossRef
7.
Zurück zum Zitat De Kraaker J, Graf N, Von Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate risk and anaplastic Wilms tumors (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004;364(9441):1229–35.CrossRef De Kraaker J, Graf N, Von Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate risk and anaplastic Wilms tumors (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004;364(9441):1229–35.CrossRef
8.
Zurück zum Zitat Reinhard H, Semler O, Büger D, et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms tumor. Klin Pädiatr. 2004;216(3):132–40.PubMedCrossRef Reinhard H, Semler O, Büger D, et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms tumor. Klin Pädiatr. 2004;216(3):132–40.PubMedCrossRef
9.
Zurück zum Zitat Pastore G, Znaor A, Spreafico F, et al. Malignant renal tumor incidence and survival in European children. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2103–14.PubMedCrossRef Pastore G, Znaor A, Spreafico F, et al. Malignant renal tumor incidence and survival in European children. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2103–14.PubMedCrossRef
10.
Zurück zum Zitat Zoubek A, Kajtar P, Flucher-Wolfram B, et al. Response of untreated stage IV Wilms’ tumor to single dose carboplatin assessed by “up front” window therapy. Med Pediatr Oncol. 1995;25(1):8–11.PubMedCrossRef Zoubek A, Kajtar P, Flucher-Wolfram B, et al. Response of untreated stage IV Wilms’ tumor to single dose carboplatin assessed by “up front” window therapy. Med Pediatr Oncol. 1995;25(1):8–11.PubMedCrossRef
11.
Zurück zum Zitat Urban CE, Lackner H, Schwinger W, et al. Partial nephrectomy in well-responding stage I Wilms’ tumors: report of three cases. Pediatr Hematol Oncol. 1995;12(2):143–52.PubMedCrossRef Urban CE, Lackner H, Schwinger W, et al. Partial nephrectomy in well-responding stage I Wilms’ tumors: report of three cases. Pediatr Hematol Oncol. 1995;12(2):143–52.PubMedCrossRef
12.
Zurück zum Zitat Warmann SW, Furtwängler R, Blumenstock G, et al. Tumor biology influences the prognosis of nephroblastoma patients with primary pulmonary metastases: results from SIOP 93-01/GPOH and SIOP 2001/GPOH. Ann Surg. 2011;254(1):155–62.PubMedCrossRef Warmann SW, Furtwängler R, Blumenstock G, et al. Tumor biology influences the prognosis of nephroblastoma patients with primary pulmonary metastases: results from SIOP 93-01/GPOH and SIOP 2001/GPOH. Ann Surg. 2011;254(1):155–62.PubMedCrossRef
13.
Zurück zum Zitat Fuchs J, Szavay P, Luithle T, et al. Surgical implications for liver metastases in nephroblastoma—data from the SIOP/GPOH study. Surg Oncol. 2008;17(1):33–40.PubMedCrossRef Fuchs J, Szavay P, Luithle T, et al. Surgical implications for liver metastases in nephroblastoma—data from the SIOP/GPOH study. Surg Oncol. 2008;17(1):33–40.PubMedCrossRef
14.
Zurück zum Zitat Fuchs J, Kienecker K, Furtwängler K, et al. Surgical aspects in the treatment of patients with unilateral wilms tumor: a report from the SIOP 93-01/German Society of Pediatrics Oncology and Hematology. Ann Surg. 2009;249:666–71.PubMedCrossRef Fuchs J, Kienecker K, Furtwängler K, et al. Surgical aspects in the treatment of patients with unilateral wilms tumor: a report from the SIOP 93-01/German Society of Pediatrics Oncology and Hematology. Ann Surg. 2009;249:666–71.PubMedCrossRef
15.
Zurück zum Zitat Paya K, Horcher E, Rauhofer U, et al. Bilateral Wilms’ tumor—surgical aspects. Eur J Pediatr Surg. 2001;11(2):99–104.PubMedCrossRef Paya K, Horcher E, Rauhofer U, et al. Bilateral Wilms’ tumor—surgical aspects. Eur J Pediatr Surg. 2001;11(2):99–104.PubMedCrossRef
16.
Zurück zum Zitat Cozzi F, Schiavetti A, Morini F, et al. Re: partial nephrectomy for unilateral wilms tumor: results of study SIOP 93-01/GPOH. J Urol. 2004;171:2383.PubMedCrossRef Cozzi F, Schiavetti A, Morini F, et al. Re: partial nephrectomy for unilateral wilms tumor: results of study SIOP 93-01/GPOH. J Urol. 2004;171:2383.PubMedCrossRef
17.
Zurück zum Zitat Delemarre JF, Sandstedt B, Harms B, et al. The new SIOP (Stockholm) working classification of renal tumours of childhood. International Society of Paediatric Oncology. Med Pediatr Oncol. 1996;26(2):145–6.PubMedCrossRef Delemarre JF, Sandstedt B, Harms B, et al. The new SIOP (Stockholm) working classification of renal tumours of childhood. International Society of Paediatric Oncology. Med Pediatr Oncol. 1996;26(2):145–6.PubMedCrossRef
18.
Zurück zum Zitat Bernstein L, Linet M, Smith MA, et al. Renal tumors. Cancer incidence and survival among children and adolescents: 1975–1995. United States SEER Program. 1999;79–90. Bernstein L, Linet M, Smith MA, et al. Renal tumors. Cancer incidence and survival among children and adolescents: 1975–1995. United States SEER Program. 1999;79–90.
19.
Zurück zum Zitat Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356–62.PubMedCrossRef Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356–62.PubMedCrossRef
Metadaten
Titel
Results of children with renal tumors treated in the Austrian–Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria
verfasst von
Claudia Zimmermann
Ulrike Pötschger
Gabriele Amann
Ernst Horcher
Karin Dieckmann
Karoly Lakatos
Christian Urban
Herwig Lackner
Michael Höllwarth
Bernhard Meister
Roman Crazzolara
Georg Ebetsberger
Franz Martin Fink
Neil Jones
Agnes Gamper
Reinhard Moser
Reinhold Kerbl
Barbara Jauk
Walter Pobegen
Martin Henkel
Bernd Ausserer
Waltraud Friesenbichler
Judith Böhm
Norbert Graf
Wolfgang Holter
Helmut Gadner
Andreas Zoubek
Leo Kager, MD
Publikationsdatum
01.12.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0057-5

Weitere Artikel der Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012 Zur Ausgabe